至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Nat Commun. 2021-05; 
Yu Guo, Lisu Huang, Guangshun Zhang, Yanfeng Yao, He Zhou, Shu Shen, Bingqing Shen, Bo Li, Xin Li, Qian Zhang, Mingjie Chen, Da Chen, Jia Wu, Dan Fu, Xinxin Zeng, Mingfang Feng, Chunjiang Pi, Yuan Wang, Xingdong Zhou, Minmin Lu, Yarong Li, Yaohui Fang, Yun-Yueh Lu, Xue Hu, Shanshan Wang, Wanju Zhang, Ge Gao, Francisco Adrian, Qisheng Wang, Feng Yu, Yun Peng, Alexander G Gabibov, Juan Min, Yuhui Wang, Heyu Huang, Alexey Stepanov, Wei Zhang, Yan Cai, Junwei Liu, Zhiming Yuan, Chen Zhang, Zhiyong Lou, Fei Deng, Hongkai Zhang, Chao Shan, Liang Schweizer, Kun Sun, Zihe Rao
Products/Services Used Details Operation
Mutant Libraries In separate studies, pseudoviruses encoding wild-type or different mutant S protein (GenScript, SARS-CoV-2/Wild-type (WT), SARS-CoV-2/D614G, SARS-CoV-2/V367F, SARS-CoV-2/W436R, and SARS-CoV-2/D364Y) were incubated with a serial dilution of purified antibodies Get A Quote

摘要

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Receptor-Binding Domain, shown by high-resolution complex structure analysis. We further demonstrate the binding and neutralizing activities of P4A1 against wild type and mutant Spike proteins or pseudoviruses. P4A1 was subsequ... More

关键词